Hot Features
Premium
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Period:
Draw Mode:
| Volume | 16,887 |
|
|||||
| News | - | ||||||
| Day High | 3.5694 | Low High |
|||||
| Day Low | 3.47 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Tenax Therapeutics Inc | TENX | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.12 | -3.33% | 3.48 | 18:21:27 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 3.55 | 3.47 | 3.5694 | 3.48 | 3.60 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 163 | 16,887 | US$ 3.53 | US$ 59,563 | - | 3.47 - 61.152 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 18:39:37 | 4 | US$ 3.57 | USD |
Tenax Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 1.04M | 298.28k | - | 0 | -7.71M | -25.85 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Tenax Therapeutics News
| Date | Time | Source | News Article |
|---|---|---|---|
| 4/09/2024 | 07:30 | GlobeNewswire Inc. | Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the.. |
| 3/28/2024 | 07:30 | GlobeNewswire Inc. | Tenax Therapeutics Provides Business and Clinical.. |
| 3/12/2024 | 07:30 | GlobeNewswire Inc. | Tenax Therapeutics to Present at the 36th Annual Roth.. |
| 2/29/2024 | 08:00 | GlobeNewswire Inc. | Tenax Therapeutics Announces Oral Presentation of.. |
| 2/26/2024 | 15:31 | Edgar (US Regulatory) | Form 424B3 - Prospectus [Rule 424(b)(3)] |
| 2/23/2024 | 15:30 | Edgar (US Regulatory) | Form 8-K - Current report |
| 2/20/2024 | 15:01 | Edgar (US Regulatory) | Form SC 13G - Statement of acquisition of beneficial.. |
| 2/20/2024 | 07:33 | Edgar (US Regulatory) | Form 8-K - Current report |
| 2/20/2024 | 07:30 | GlobeNewswire Inc. | Tenax Therapeutics Announces Global License Amendment that.. |
| 2/16/2024 | 10:28 | Edgar (US Regulatory) | Form SC 13G - Statement of acquisition of beneficial.. |
| 2/15/2024 | 18:36 | Edgar (US Regulatory) | Form SC 13G - Statement of acquisition of beneficial.. |
| 2/12/2024 | 15:46 | Edgar (US Regulatory) | Form 8-K - Current report |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical TENX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 3.58 | 3.7778 | 3.47 | 3.57 | 12,679 | -0.10 | -2.79% |
| 1 Month | 4.15 | 4.249 | 3.47 | 3.81 | 32,532 | -0.67 | -16.14% |
| 3 Months | 11.49 | 21.4599 | 3.47 | 8.62 | 371,890 | -8.01 | -69.71% |
| 6 Months | 22.40 | 61.152 | 3.47 | 43.65 | 3,757,963 | -18.92 | -84.46% |
| 1 Year | 25.92 | 61.152 | 3.47 | 41.16 | 2,179,207 | -22.44 | -86.57% |
| 3 Years | 3,024.00 | 3,680.00 | 3.47 | 157.92 | 1,571,513 | -3,020.52 | -99.88% |
| 5 Years | 2,624.00 | 5,888.00 | 3.47 | 1,057.02 | 1,362,228 | -2,620.52 | -99.87% |
Tenax Therapeutics Description
| Tenax Therapeutics, Inc., is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need. The Company has a world-class scientific advisory team including recognized global experts in pulmonary hypertension. The Company owns North American rights to develop and commercialize levosimendan and has recently released topline data regarding their Phase 2 clinical trial for the use of levosimendan in the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF). For more information, visit www.tenaxthera.com. |
